|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The stem cell market was valued at about USD 16.19 billion in 2021, expected to witness a revenue of USD 29.53 billion in 2027 with a CAGR of 10.21% over the forecast period, 2022-2027.
The growth of the market is attributed to the rising number of clinical trials and the growing adoption of stem cell therapies globally. In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19. According to a 2020 research article published in the scientific journal Aging and Disease (2020), mesenchymal stem cells are a safe and effective approach to the treatment of COVID-19. At least 10 projects have been registered in the official international registry for clinical trials, implicating the use of mesenchymal stem cells to patients with coronavirus pneumonia. However, it is still at an initial stage of study in relation to the market studied.
The area of stem cell-based therapies garners significant investments, and various clinical trials that require considerable support for expenditure are currently underway. Companies are fund raising to develop stem cell based therapies to tackle many disease. For instance, in January 2022 Cellino Biotech, an cell therapy manufacturing company, has raised USD 80 million Series A financing round. Cellino plans to expand access to stem cell-based therapies with the intention to build the first autonomous human cell foundry in 2025. As the applications of stem cell technologies in the treatment of diseases have ultimately increased, the overall adoption rate of these technologies across the world. This has led to increased investments by the market player for the development of novel therapies in this area.
Stem cells are majorly used in regenerative medicine, especially in the field of dermatology. However, oncology is expected to grow at the highest rate due to a large number of pipeline products present for the treatment of tumors or cancers. With the increase in the number of regenerative medicine centers, the stem cell market is also expected to increase in the future.
One of the richest sources of stem cells is the umbilical cord, which possesses unique qualities and has greater advantages over embryonic stem cells or adult stem cells. There are an increasing number of stem cell banks, which collaborate with hospitals and increase awareness about the storage of cord blood units in families, particularly in the emerging markets. The support is increasing with the rising number of medical communities and government initiatives active in promoting the use of stem cells for the treatment of more than 100 diseases. According to the National Institutes of Health updates in 2021, there is an increase in the number of clinical trials for testing future treatment possibilities of cord blood. Over 200 National Institutes of Health (NIH)-funded clinical trials with cord blood are currently being conducted in the United States alone.
Scope of the Report
As per the scope of the report, stem cells are biological cells that can differentiate into other types of cells. Additionally, various types of stem cells are used for therapeutic purposes. With multiple applications at the clinical stage for various diseases, these are being explored extensively by a large number of biopharmaceutical companies in recent times. The market is segmented by product type (adult stem cell, human embryonic cell, pluripotent stem cell, and other product types), application (neurological disorders, orthopedic treatments, oncology disorders, injuries and wounds, cardiovascular disorders, and other applications), treatment type (allogeneic stem cell therapy, auto logic stem cell therapy, and syngeneic stem cell therapy) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD billion) for the above segments.
|By Product Type|
|Adult Stem Cell|
|Human Embryonic Cell|
|Pluripotent Stem Cell|
|Other Product Types|
|Injuries and Wounds|
|By Treatment Type|
|Allogeneic Stem Cell Therapy|
|Autologic Stem Cell Therapy|
|Syngeneic Stem Cell Therapy|
Key Market Trends
The Oncology Disorders Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period
The global cancer burden has been increasing, and thus, cancer therapies must be modified according to regional and national priorities. As per the data published by the International Agency for Research on Cancer 2020, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. Breast, colorectal, lung, cervical, and thyroid cancers are common among women whereas, lung cancer and prostate cancer are the most common among men, together accounting for nearly one-third of all male cancers. As per the National Cancer Institute 2020, more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America. Additionally, 70% of the deaths due to cancer, globally, occur in these regions.
Bone marrow transplant or stem cell transplant is a treatment for some types of cancer, like leukemia, multiple myeloma, neuroblastoma, or some types of lymphoma. For cancer treatments, both autologous and allogeneic stem cell transplants are done. Autologous transplants are preferred in the case of leukemias, lymphomas, multiple myeloma, testicular cancer, and neuroblastoma.
The major disadvantage associated with autologous stem cell transplants in cancer therapy is that cancer cells sometimes also get collected, along with stem cells, which may further put it back into the body during the therapy.
In case of allogeneic stem cell transplants, the donor can often be asked to donate more stem cells or even white blood cells, as per the requirement, and stem cells from healthy donors are free of cancer cells. However, the transplanted donor stem cells could die or be destroyed by the patient’s body before settling in the bone marrow.
Moreover, due to the growing focus of stem cell-based research and the rising demand for novel treatments, several companies, such as Stemline Therapeutics, have been focusing on developing technologies and treatments to attack cancer cells, which may help the market grow. However, owing to the COVID-19 pandemic, the detection and treatment of new cancer cases are impended, which may slightly impact the segment growth in the year.
To understand key trends, Download Sample Report
North America Captured The Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall stem cell market, with the United States contributing to the largest share in the market. The United States and Canada have developed and well-structured healthcare systems. These systems also encourage research and development. The increasing number of cancer cases is providing opportunities for market players. The major market players are focusing on R&D activities to introduce new stem cell therapies in the market. Moreover, according to Globocan 2020, the estimated number of cancer cases in the United States is 2,281,658. The most common cancer types in the United States are breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, and skin cancer.
For instance, the National Cancer Institute (NCI) had stated that the national expenditure on cancer care was expected to reach USD 156 billion by 2020. This factor is expected to boost the growth of the market in the future. In December 2019, the researchers at the National Eye Institute (NEI) launched a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD), a leading cause of vision loss among people aged 65 years and above.
In addition, the current situation of COVID-19 is another factor driving the growth of the market in the country, as research activities are undergoing for the treatment of COVID-19. Stem cell therapy can also be a promising approach for the treatment of COVID-19 in the future. For instance, on May 6, 2020, Lineage Cell Therapeutics received a grant of USD 5 million from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage’s allogeneic dendritic cell therapy for the development of a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.
To understand geography trends, Download Sample Report
The stem cell market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific (Qiagen NV), Sigma Aldrich (a subsidiary of Merck KGaA), Becton, Dickinson and Company, and Stem Cell Technologies, is in turn, increasing the overall competitive rivalry in the market. The product advancements and improvement in stem cell technology by the major players are also increasing the competitive rivalry.
In August 2021, Scientists at University of California San Diego School of Medicine have identified the underlying issue and developed a method to keep cultured cells healthy for patients seeking stem cell transplants and may hint at a new way to ward off aging.
In March 2021, OrganaBio launched HematoPAC HSC-CB CD34 hematopoietic stem cell (HSC) product, which is helpful in supporting hematopoietic stem cell based allogeneic cell therapies.
Table of Contents
1.1 Study Assumptions and market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Awareness about Umbilical Stem Cell and Growing Demand for Regenerative Treatment Options
4.2.2 Rising R&D Initiatives to Develop Stem Cell Therapies and Increasing Approvals for Clinical Trials in Stem Cell Research
4.3 Market Restraints
4.3.1 Expensive Procedures
4.3.2 Regulatory Complications and Ethical and Moral Framework
4.4 Industry Attractiveness- Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product Type
5.1.1 Adult Stem Cell
5.1.2 Human Embryonic Cell
5.1.3 Pluripotent Stem Cell
5.1.4 Other Product Types
5.2 By Application
5.2.1 Neurological Disorders
5.2.2 Orthopedic Treatments
5.2.3 Oncology Disorders
5.2.4 Injuries and Wounds
5.2.5 Cardiovascular Disorders
5.2.6 Other Applications
5.3 By Treatment Type
5.3.1 Allogeneic Stem Cell Therapy
5.3.2 Autologic Stem Cell Therapy
5.3.3 Syngeneic Stem Cell Therapy
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Smith & Nephew PLC
6.1.2 Pluristem Therapeutics Inc.
6.1.3 Thermo Fisher Scientific
6.1.4 Qiagen NV
6.1.5 Merck KGaA (Sigma Aldrich)
6.1.6 Becton, Dickinson and Company
6.1.7 Stem Cell Technologies Inc.
6.1.8 AllCells LLC
6.1.9 Miltenyi Biotec
6.1.10 International Stem Cell Corporation
6.1.11 ReNeuron Group plc
6.1.12 Regen BioPharma
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Stem Cell Market market is studied from 2019 - 2027.
What is the growth rate of Global Stem Cell Market?
The Global Stem Cell Market is growing at a CAGR of 10.21% over the next 5 years.
What is Global Stem Cell Market size in 2019?
The Global Stem Cell Market is valued at 16 Billion USD in 2019.
What is Global Stem Cell Market size in 2027?
The Global Stem Cell Market is valued at 29 Billion USD in 2027.
Which region has highest growth rate in Global Stem Cell Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Stem Cell Market?
North America holds highest share in 2021.
Who are the key players in Global Stem Cell Market?
Thermo Fisher Scientific, Becton, Dickinson and Company, Stemcell Technologies Inc., Merck KGaA (Sigma Aldrich), PLURISTEM THERAPEUTICS INC. are the major companies operating in Global Stem Cell Market.